Updated on 2022/05/30

写真a

 
KASUYA, Hideki
 
Organization
Graduate School of Medicine Program in Integrated Medicine Professor
Graduate School
Graduate School of Medicine
Undergraduate School
School of Medicine Department of Medicine
Title
Professor
Profile
Professor of International Medical Education; Vice Dean of Medical School, Vice Presidential Advisor for International Affairs, Director: Office of International Affairs, Director: Laboratory of Cancer Immunotherapy; Full Member: FACS (Faculty of the American College of Surgery), Board Member:Japanese Society for Gene and Cell Therapy, Board Member:Japanese Medical University International Collaborative Assembly, Board Member:Nagoya University Medical Association. From 2000-2003, Postdoctoral fellow at the Massachusetts General Hospital, Harvard Medical School (Department of Surgery). Current research interests include cancer immunotherapy for pancreatic cancer and comparison of doctoral education systems around the world, and in 2015 he established Japan's first joint doctoral degree program in medicine with the University of Adelaide.

Degree 3

  1. FACS ( 2010.10   American College of Surgeon ) 

  2. A Philosophy of Doctor ( 2000.3   Nagoya University ) 

  3. A Doctor of Medicine ( 1990.3   Aichi Medical University ) 

Research Areas 4

  1. Others / Others  / Laboratory Animal Studies

  2. Others / Others  / Virology

  3. Others / Others  / Digestive Organ Surgery

  4. Others / Others  / Human Genetics

Current Research Project and SDGs 2

  1. Cancer Treatment with Oncolytic viruses and Immune Cells

  2. Comparison of PhD Education Worldwide

Research History 18

  1. The Chinese University of Hong Kong   Clinical Medicine   Emeritus Professor

    2018.4

      More details

    Country:China

  2. Nagoya University   Professor

    2017.6

      More details

    Country:Japan

  3. Nagoya University   Professor

    2017.6

  4. Nagoya University   Graduate School of Medicine

    2016.4

  5. Nagoya University   Graduate School of Medicine   Ofice of International Affair, Chairman

    2013.4

  6. Professor for Cancer Immune TherapyInternational Center for Medical Technologies, in Baylor College of Medicine

    2010.2

  7. 名古屋大学大学院 医学系研究科 准教授

    2009.4 - 2017.5

      More details

    Country:Japan

  8. Nagoya University

    2009.4 - 2017.5

  9. Associate Professor, Nagoya University Graduate School of Medicince

    2007.5 - 2009.3

      More details

    Country:Japan

  10. Associate Dean, Nagoya University Graduate School of Medicince

    2007.5

      More details

    Country:Japan

  11. Nagoya University   Associate Dean

    2007.5

  12. Chief Director, Division of Medical Support, Seto Reformatory, Seto, Japan

    2004.4 - 2007.4

      More details

    Country:Japan

  13. Assistant Professor, Department of Surgery II, Nagoya University School of Medicince

    2004.4 - 2007.4

      More details

    Country:Japan

  14. Department of Surgery II, Nagoya University Hospital, Nagoya, Japan

    2003.10 - 2004.3

      More details

    Country:Japan

  15. Research Fellow, MGH, Harvard Medical School, U.S.A.

    2000.4 - 2003.9

  16. 名古屋大学医学部第二外科・医員

    1996.4 - 2000.3

      More details

    Country:Japan

  17. Department of Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan

    1995.7 - 1996.3

      More details

    Country:Japan

  18. Department of Surgery, Holy Spirit Hospital, Nagoya, Japan

    1990.3 - 1995.6

      More details

    Country:Japan

▼display all

Education 2

  1. Nagoya University   Graduate School, Division of Medical Sciences   Program in function Construction Medicine

    1996.4 - 2000.3

      More details

    Country: Japan

  2. Aichi Medical University   Faculty of Medicine   Medicine

    1984.4 - 1990.3

      More details

    Country: Japan

Professional Memberships 10

  1. American Association for Cancer Research

  2. American Society of Clinical Oncology

  3. アメリカ外科学会 (FACS)

  4. Japan Surgical Society

  5. Japanese Society of Gastroenterological Surgery

  6. Japan Society of Clinical Oncology

  7. Japan Cancer Assiciation

  8. The Japan Society of Gene Therapy

  9. Japan Pancreas Society

  10. Japan Surgical Association

▼display all

Awards 3

  1. Journal of Gene Medicine Award

    2009  

  2. Marie Curie Award

    2006  

  3. Out standing Intellectuals Award

    2003  

 

Papers 64

  1. An international medical education perspective on training in child and adolescent psychiatry

    Aleksic Branko, Kasuya Hideki

    ASIA-PACIFIC PSYCHIATRY   Vol. 14 ( 2 ) page: e12509   2022.6

     More details

  2. Oncolytic HSV HF10 (canerpaturev, C-REV) promotes accumulation of CD8+PD-1-tumor-infiltrating T cells in a SCC model

    Mohamed Abdelmoneim A., Eissa Ibrahim R., Mukoyama Nobuaki, Abdelmoneim Mohamed, Naoe Yoshinori, Matsumura Shigeru, Bustosvillalobos Itzel, Ichinose Toru, Miyajima Noriyuki, Morimoto Daishi, Tanaka Maki, Fujimoto Yasushi, Sone Michihiko, Kodera Yasuhiro, Kasuya Hideki

    CANCER SCIENCE   Vol. 113   page: 526 - 526   2022.2

     More details

    Language:Japanese  

    Web of Science

  3. S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model

    Miyajima Noriyuki, Eissa Ibrahim Ragab, Abdelmoneim Mohamed, Naoe Yoshinori, Ichinose Toru, Matsumura Shigeru, Bustos-Villalobos Itzel, Mukoyama Nobuaki, Morimoto Daishi, Shibata Masahiro, Takeuchi Dai, Tsunoda Nobuyuki, Kikumori Toyone, Tanaka Maki, Kodera Yasuhiro, Kasuya Hideki

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 83 ( 4 ) page: 683 - 696   2021.11

     More details

  4. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8(+)PD-1(-) tumor-infiltrating T cells in PD-L1-enriched tumor microenvironment

    Eissa Ibrahim Ragab, Mukoyama Nobuaki, Abdelmoneim Mohamed, Naoe Yoshinori, Matsumura Shigeru, Bustos-Villalobos Itzel, Ichinose Toru, Miyajima Noriyuki, Morimoto Daishi, Tanaka Maki, Fujimoto Yasushi, Sone Michihiko, Kodera Yasuhiro, Kasuya Hideki

    INTERNATIONAL JOURNAL OF CANCER   Vol. 149 ( 1 ) page: 214 - 227   2021.7

     More details

  5. C-REV Retains High Infectivity Regardless of the Expression Levels of cGAS and STING in Cultured Pancreatic Cancer Cells

    Morimoto Daishi, Matsumura Shigeru, Bustos-Villalobos Itzel, Sibal Patricia Angela, Ichinose Toru, Naoe Yoshinori, Eissa Ibrahim Ragab, Abdelmoneim Mohamed, Mukoyama Nobuaki, Miyajima Noriyuki, Tanaka Maki, Kodera Yasuhiro, Kasuya Hideki

    CELLS   Vol. 10 ( 6 )   2021.6

     More details

  6. Problem-Based Learning in Child and Adolescent Psychiatry: A Perspective from Japan

    Iwatsuki Junko, Kondo Takeshi, Takahashi Noriyuki, Takami Hideki, Nishigori Hiroshi, Bustos-Villalobos Itzel, Aleksic Branko, Kasuya Hideki, Ban Nobutaro, Yagi Tetsuya, Skokauskas Norbert

    ADVANCES IN MEDICAL EDUCATION AND PRACTICE   Vol. 12   page: 1329 - 1335   2021

     More details

  7. S-1 Facilitates C-REV Induced Anti-Tumor Efficacy in Triple Negative Breast Cancer Model

    Kasuya Hideki, Naoe Yoshinori, Matsumura Shigeru, Bustos Itzel, Eissa Ibrahim, Mohamed Ali, Tanaka Maki

    MOLECULAR THERAPY   Vol. 28 ( 4 ) page: 163 - 163   2020.4

     More details

    Language:Japanese  

    Web of Science

  8. Phase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancer International journal

    Hijioka S., Ueno M., Ioka T., Hirooka Y., Ohno E., Okusaka T., Maruki Y., Kobayashi S., Ashida R., Yashika J., Furuse J., Ikeda M., Kasuya H., Tanaka M., Hashimoto Y.

    ANNALS OF ONCOLOGY   Vol. 30   2019.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Web of Science

  9. Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer International journal

    Hashimoto Y., Hijioka S., Hirooka Y., Ohno E., Ioka T., Kobayashi S., Okusaka T., Maruki Y., Yashika J., Ashida R., Furuse J., Ikeda M., Kasuya H., Tanaka M., Ueno M.

    ANNALS OF ONCOLOGY   Vol. 30   page: 269 - +   2019.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Web of Science

  10. Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth Reviewed International journal

    Wu Zhiwen, Ichinose Toru, Naoe Yoshinori, Matsumura Shigeru, Villalobos Itzel Bustos, Eissa Ibrahim Ragab, Yamada Suguru, Miyajima Noriyuki, Morimoto Daishi, Mukoyama Nobuaki, Nishikawa Yoko, Koide Yusuke, Kodera Yasuhiro, Tanaka Maki, Kasuya Hideki

    MOLECULAR THERAPY-ONCOLYTICS   Vol. 13   page: 107 - 115   2019.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.omto.2019.04.004

    Web of Science

    PubMed

  11. Joint Degree Program for Graduate Students at the Nagoya University Graduate School of Medicine Reviewed

    Kasuya Hideki, Aleksic Branko, Sumigama Seiji, Bustos Itzel, Hasegawa Hitoki, Kasai Mika P., Kobayashi Miho, Samizo Yumiko

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 81 ( 2 ) page: 183 - 192   2019.5

     More details

  12. STING is dispensable for low susceptibility for HF10 in pancreatic cell lines

    Matsumura Shigeru, Morimoto Daishi, Noe Yoshinori, Ichinose Toru, Tanaka Maki, Kodera Yasuhiro, Kasuya Hideki

    CANCER SCIENCE   Vol. 109   page: 1328 - 1328   2018.12

     More details

    Language:Japanese  

    Web of Science

  13. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.

    Eissa IR, Bustos-Villalobos I, Ichinose T, Matsumura S, Naoe Y, Miyajima N, Morimoto D, Mukoyama N, Zhiwen W, Tanaka M, Hasegawa H, Sumigama S, Aleksic B, Kodera Y, Kasuya H

    Cancers   Vol. 10 ( 10 )   2018.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.3390/cancers10100356

    Web of Science

    PubMed

  14. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer International journal

    Hirooka Yoshiki, Kasuya Hideki, Ishikawa Takuya, Kawashima Hiroki, Ohno Eizaburo, Villalobos Itzel B., Naoe Yoshinori, Ichinose Toru, Koyama Nobuto, Tanaka Maki, Kodera Yasuhiro, Goto Hidemi

    BMC CANCER   Vol. 18 ( 1 ) page: 596   2018.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s12885-018-4453-z

    Web of Science

    PubMed

  15. Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity Reviewed

    Yoshihiro Hotta, Hideki Kasuya, Itzel Bustos, Yoshinori Naoe, Toru Ichinose, Maki Tanaka, Yasuhiro Kodera

    Oncolytic Virotherapy   Vol. 6   page: 31—38   2017.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  16. Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity

    Hotta Yoshihiro, Kasuya Hideki, Bustos Itzel, Naoe Yoshinori, Ichinose Toru, Tanaka Maki, Kodera Yasuhiro

    ONCOLYTIC VIROTHERAPY   Vol. 6   page: 31 - 38   2017

     More details

  17. Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials Reviewed

    Ibrahim Ragab Eissa, Yoshinori Naoe, Itzel Bustos-Villalobos, Toru Ichinose, Maki Tanaka, Wu Zhiwen, Nobuaki Mukoyama, Taishi Morimoto, Noriyuki Miyajima, Hasegawa Hitoki, Seiji Sumigama, Branko Aleksic, Yasuhiro Kodera and Hideki Kasuya

    Front. Oncol.   Vol. 7   page: 149   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3389/fonc.2017.00149

    PubMed

  18. Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft Reviewed

    Gewen Tan, Hideki Kasuya, Tevfik Tolga Sahin, Kazuo Yamamura, Zhiwen Wu, Yusuke Koide, Yoshihiro Hotta, Toshio Shikano, Suguru Yamada, Akiyuki Kanzaki, Tsutomu Fujii, Hiroyuki Sugimoto, Shuji Nomoto, Yoko Nishikawa, Maki Tanaka, Naoko Tsurumaru, Toshie Kuwahara, Saori Fukuda, Toru Ichinose, Toyone Kikumori, Shin Takeda, Akimasa Nakao and Yasuhiro Korea

    International Journal of Cancer   Vol. 136 ( 7 ) page: 1718–1730   2015.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  19. Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer Reviewed

    Hideki Kasuya, Yasuhiro Kodera, Akimasa Nakao, Kazuo Yamamura, Tan Gewen, Wu Zhiwen, Yoshihiro Hotta, Suguru Yamada, Tsutomu Fujii, Saori Fukuda, Naoko Tsurumaru, Toshie Kuwahara, Toyone Kikumori, Yusuke Koide, Yasushi Fujimoto, Tsutomu Nakashima, Yoshiki Hirooka, Hiroshi Shiku, Maki Tanaka, Kazuto Takesako, Touru Kondo, Branko Aleksic, Hiroki Kawashima, Hidemi Goto, Yukihiro Nishiyama

    Hepato-Gastroenterology   Vol. 61 ( 131 ) page: 599-605   2014.5

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  20. Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10. Reviewed

    Yamamura K, Kasuya H, Sahin TT, Tan G, Hotta Y, Tsurumaru N, Fukuda S, Kanda M, Kobayashi D, Tanaka C, Yamada S, Nakayama G, Fujii T, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Tanaka M, Kodera Y.

    Ann Surg Oncol   Vol. 21 ( 2 ) page: 691-8   2014.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1245/s10434-013-3329-3

  21. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer

    Tevfik Tolga Sahin, Hideki Kasuya, Naohiro Nomura, Toshio Shikano, Tan Gewen, Akiyuki Kanzaki, Tsutomu Fujii, Takashi Sugae, Tsuneo Imai, Shuji Nomoto, Shin Takeda, Hiroyuki Sugimoto, Toyone Kikumori, Yasuhiro Kodera, Yukihiro Nishiyama, Akimasa Nakao

    Cancer Gene Therapy   Vol. 19 ( 4 ) page: 229-237   2012.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  22. Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes

    Akiyuki Kanzaki, Hideki Kasuya, Kazuo Yamamura, Tevfik Tolga Sahin, Naohiro Nomura, Toshio Shikano, Takashi Shirota, Tan Gewen, Saori Fukuda, Makoto Misawa, Yoko Nishikawa, Suguru Yamada, Tsutomu Fujii, Hiroyuki Sugimoto, Shuji Nomoto, Shin Takeda Yasuhiro Kodera, Akimasa Nakao

    Cancer Gene Therapy   Vol. 19 ( 4 ) page: 292-298   2012.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  23. Prognostic implications of lymph node metastases in carcinoma of the body and tail of the pancreas.

    Sahin TT, Fujii T, Kanda M, Nagai S, Kodera Y, Kanzaki A, Yamamura K, Sugimoto H, Kasuya H, Nomoto S, Takeda S, Morita S, Nakao A.

    Pancreas     page: 40(7):1029-33   2011.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  24. Oncolytic Herpes Virus Induces Effective Anti-Cancer Immunity against Murine Colon Cancer.

    Shirota T, Kasuya H, Kodera Y, Nishikawa Y, Shikano T, Sahin TT, Gewen T, Yamamura K, Kanzaki A, Yamada S, Fujii T, Sugimoto H, Nomoto S, Takeda S, Nakao A.

    Hepatogastroenterology     page: 58(110-111)   2011.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.5754/hge11168

  25. 特集:膵疾患画像診断における最近の進歩 膵癌に対する術中超音波検査の最近の進歩

    杉本博行,竹田 伸,野本周嗣,粕谷英樹,藤井 努,中尾昭公

    膵臓   Vol. 26 ( 1 ) page: 66-71   2011.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  26. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer.

    Nakao A, Kasuya H, Sahin TT, Nomura N, Kanzaki A, Misawa M, Shirota T, Yamada S, Fujii T, Sugimoto H, Shikano T, Nomoto S, Takeda S, Kodera Y, Nishiyama Y.

    Cancer Gene Ther.     page: 18(3):167-75   2010.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  27. Medial prefrontal cortex-dorsal anterior cingulate cortex connectivity during behavior selection without an objective correct answer.

    Nakao T, Osumi T, Ohira H, Kasuya Y, Shinoda J, Yamada J, Northoff G.

    Neurosci Lett.     page: 4;482(3):220-4   2010.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  28. Clinical Trial of HF10 Oncolytic Virus Therapy for Advanced Pancreatic Cancer, Cancer Gene Ther. Reviewed

    19. Akimasa Nakao, Hideki Kasuya, Tevfik Tolga Sahin, Naohiro Nomura, Akiyuki Kanzaki, Makoto Misawa, Takashi Shirota, Suguru Yamada, Tsutomu Fujii, Hiroyuki Sugimoto, Toshio Shikano, Shuji Nomoto, Shin Takeda, Yasuhiro Kodera, Yukihiro Nishiyama

    Cancer Gene Ther.     page: 2010, July   2010.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  29. High Therapeutic Potential for Systemic Delivery of a Liposome-conjugated Herpes Simplex Virus. Reviewed

    20. Toshio Shikano, Hideki Kasuya, Tevfik Tolga Sahin, Naohiro Nomura, Akiyuki Kanzaki, Makoto Misawa, Yoko Nishikawa, Takashi Shirota, Suguru Yamada, Tsutomu Fujii, Hiroyuki Sugimoto, Naohito Kanazumi, Shuji Nomoto, Shin Takeda and Akimasa Nakao.

    CCDT     page: 2010 [June Accepted]   2010.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  30. 腫瘍溶解性ウィルス、HF10を使用したトランスレーショナルリサーチ Reviewed

    17. 粕谷英樹、竹田 伸、今井常夫、野本周嗣、野村尚弘、杉本博行、三澤 真、山田 豪、神崎章之、藤井 努、Tevfik Tolga Sahin 、西山幸廣、中尾昭公

    外科遺伝子治療フロンティア     page: 2010 1月   2010.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  31. 膵癌の腫瘍溶解性ウイルス療法 Reviewed

    18. 粕谷英樹、竹田 伸、今井常夫、野本周嗣、野村尚弘、杉本博行、三澤 真、山田 豪、神崎章之、藤井 努、Tevfik Tolga Sahin 、西山幸廣、中尾昭公

    膵臓     page: 2010 1月   2010.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  32. Pancreatic head resection with segmental duodenectomy for pancreatic neoplasms. Reviewed

    16. Nakao A, Takeda S, Nomoto S, Kanazumi N, Kasuya H, Sugimoto H, Fujii T, Yamada S.

    J Hepatobiliary Pancreat Surg.     page: 2009 Nov 3. [Epub ahead of print]   2009.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  33. Pancreatic cancer with distant metastases: a contraindication for radical surgery? Reviewed

    15. Yamada S, Fujii T, Sugimoto H, Kanazumi N, Kasuya H, Nomoto S, Takeda S, Kodera Y, Nakao A

    Hepatogastroenterology     page: 56(91-92):881-5   2009.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  34. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. Reviewed

    13. Nomura N, Fujii T, Kanazumi N, Takeda S, Nomoto S, Kasuya H, Sugimoto H, Yamada S, Nakao A.

    Hepatobiliary Pancreat Surg.     page: 2009 Apr 14   2009.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  35. The tumor suppressor NPRL2 in hepatocellular carcinoma plays an important role in progression and can be served as an independent prognostic factor. Reviewed

    14. Otani S, Takeda S, Yamada S, Sakakima Y, Sugimoto H, Nomoto S, Kasuya H, Kanazumi N, Nagasaka T, Nakao A.

    J Surg Oncol.     page: 2009 Mar 9   2009.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  36. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases. Reviewed

    12. Nomura N, Kasuya H, Watanabe I, Shikano T, Shirota T, Misawa M, Sugimoto H, Kanazumi N, Nomoto S, Takeda S, Nakao A.

    Cancer Chemother Pharmacol.     page: 63(2): 321-30   2009.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  37. Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Reviewed

    10. Watanabe I, Kasuya H, Nomura N, Kanazumi N,Takeda S, Nomoto S, Shikano T, Shirota T, Sugimoto H, Nakao A.

    Cancer Chemoth Pharm     page: 61(5):875-82   2008.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  38. Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Reviewed

    Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, Kanazumi N, Sugimoto H, Nakao A.

    Br J Cancer.   Vol. 97 ( 9 ) page: 1260-1265   2007.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  39. Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Reviewed

    11. Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, Kanazumi N, Sugimoto H, Nakao A.

    Br J Cancer.     page: 5;97(9):1260-5.   2007.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  40. Clinical implications of peritoneal cytology in potentially resectable pancreatic cancer: positive peritoneal cytology may not confer an adverse prognosis.

    7. Yamada S, Takeda S, Fujii T, Nomoto S, Kanazumi N, Sugimoto H, Kasuya H, Kodera Y, Nagasaka T, Morita S, Nakao A.

    Ann Surg     page: 246(2):254-8   2007.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  41. *Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy Reviewed

    Kasuya H, Nishiyama Y, Nomoto S, Goshima F, Takeda S, Watanabe I, Nomura N, Shikano T, Fujii T, Kanazumi N, Nakao A.

    Cancer Gene Ther   Vol. 14 ( 6 ) page: 533-542   2007.6

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  42. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models. Reviewed

    Shimoyama S, Goshima F, Teshigahara O, Kasuya H, Kodera Y, Nakao A, Nishiyama Y.

    Hepatogastroenterology   Vol. 54 ( 76 ) page: 1038-1042   2007.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  43. *Oncolytic virus therapy--foreword Invited

    Kasuya H, Takeda S, Shimoyama S, Shikano T, Nomura N, Kanazumi N, Nomoto S, Sugimoto H, Nakao A.

    Curr Cancer Drug Targets   Vol. 7 ( 2 ) page: 123-125   2007.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  44. Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer. Reviewed

    Nakao A, Takeda S, Shimoyama S, Kasuya H, Kimata H, Teshigahara O, Sawaki M, Kikumori T, Kodera Y, Nagasaka T, Goshima F, Nishiyama Y, Imai T.

    Curr Cancer Drug Targets.   Vol. 74 ( 29 ) page: 169-174   2007.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  45. Clinical application of replication competent mutant HSV in cancer therapy Invited

    Kasuya H, Nakao A.

    Nippon Rinsho   Vol. 64 ( 3 ) page: 335-339   2006.3

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  46. *The potential of oncolytic virus therapy for pancreatic cancer Reviewed

    Kasuya H, Takeda S, Nomoto S, Nakao A.

    Cancer Gene Ther   Vol. 12 ( 9 ) page: 725-736   2005.9

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  47. *Mouse models of subcutaneous spleen reservoir for multiple portal venous injections to treat liver malignancies Reviewed

    Kasuya H, Kuruppu DK, Donahue JM, Choi EW, Kawasaki H, Tanabe KK.

    Cancer Res   Vol. 65 ( 9 ) page: 3823-3827   2005.5

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  48. Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Reviewed

    Mullen JT, Donahue JM, Chandrasekhar S, Yoon SS, Liu W, Ellis LM, Nakamura H, Kasuya H, Pawlik TM, Tanabe KK.

    Cancer.   Vol. 101 ( 4 ) page: 869-877   2004.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  49. *Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen Reviewed

    Kasuya H, Pawlik TM, Mullen JT, Donahue JM, Nakamura H, Chandrasekhar S, Kawasaki H, Choi E, Tanabe KK.

    Cancer Res   Vol. 64 ( 7 ) page: 2561-2567   2004.4

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  50. Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Reviewed

    Mullen JT, Kasuya H, Yoon SS, Carroll NM, Pawlik TM, Chandrasekhar S, Nakamura H, Donahue JM, Tanabe KK.

    Ann Surg.   Vol. 236 ( 4 ) page: 502-512   2002.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  51. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Reviewed

    Pawlik TM, Nakamura H, Mullen JT, Kasuya H, Yoon SS, Chandrasekhar S, Chiocca EA, Tanabe KK.

    Cancer.   Vol. 95 ( 5 ) page: 1171-1181   2002.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  52. The potential of gene therapy in the treatment of pancreatic cancer Reviewed

    Kasuya H, Nomoto S, Nakao A.

    Drugs Today (Barc)   Vol. 38 ( 7 ) page: 457-464   2002.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  53. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. Reviewed

    Nakamura H, Kasuya H, Mullen JT, Yoon SS, Pawlik TM, Chandrasekhar S, Donahue JM, Chiocca EA, Chung RY, Tanabe KK.

    J Clin Invest.   Vol. 109 ( 7 ) page: 871-882.   2002.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  54. Gene therapy for pancreatic cancer Reviewed

    Kasuya H, Nomoto S, Kimata H, Harada A, Takeda S, Hayashi S, Nakao A.

    Hepatogastroenterology   Vol. 48 ( 40 ) page: 957-961   2001.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  55. Clinical implications of peritoneal cytology in potentially resectable pancreatic cancer: positive peritoneal cytology may not confer an adverse prognosis. Reviewed

    Yamada S, Takeda S, Fujii T, Nomoto S, Kanazumi N, Sugimoto H, Kasuya H, Kodera Y, Nagasaka T, Morita S, Nakao A.

    Ann Surg   Vol. 246 ( 29 ) page: 254-258   2000.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  56. Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy. Reviewed

    Kasuya H, Mizuno M, Yoshida J, Nishiyama Y, Nomoto S, Nakao A.

    J Surg Oncol.   Vol. 74 ( 3 ) page: 214-218.   2000.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  57. Preserving gastroduodenal artery, pancreas head resection with second potion of duodenum intestine against mucin producing pancreastic tumor. Reviewed

    Nakao A, Kaneko T, Takeda S, Inoue S, Nomoto S, Kasuya H, Koshikawa H

    The Operation   Vol. 54   page: 21-26   2000

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  58. Three clinical records of respectable metastatic pancreastic tumor. Reviewed

    Ishigure H, Kawase Y, Kanazumi N, Oshima K, Kotake K, Kasuya H, Sawada K, Nonami T, Harada A, Nakao A.

    Japan Gastro-Intestinall Surgery Association (Japan)   Vol. 33   page: 1686   2000

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  59. Resection with preserving function of pancreass. Reviewed

    Nakao A, Kaneko T, Takeda S, Inoue S, Nomoto S, Kasuya H, Koshikawa H.

    Surgery (Japan)   Vol. 62   page: 416-421   2000

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  60. Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer Reviewed

    Kasuya H, Nishiyama Y, Nomoto S, Hosono J, Takeda S, Nakao A.

    J Surg Oncol   Vol. 72 ( 3 ) page: 136-141   1999.11

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  61. Peritoneal washings cytology combined with immunocytochemical staining in pancreatic cancer. Reviewed

    Nakao A, Oshima K, Takeda S, Kaneko T, Kanazumi N, Inoue S, Nomoto S, Kawase Y, Kasuya H.

    Hepatogastroenterology.   Vol. 46 ( 29 ) page: 2974-2977   1999.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  62. Virall therapy using a replication-competennt HSV mutant (hrR3) for disseminated pancreastic cancer in mice.

    Kasuya H, Nakao A, Kimata H, Nomoto S.

    Journal of the Japan Pancreas Society   Vol. 14 ( 3 )   1999

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  63. Preserving gastroduodenal artery, pancreas head resection with second potion of duodenum intestine. Reviewed

    Nakao A, Oshima K, Kaneko T, Takeda S, Kanazumi N, Kasuya H,

    The Operation   Vol. 1   page: 33-38   1999

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  64. Postoperative delayed emptying in pylorus-preserving pancreatoduodenectomy using pancreaticogastrostomy: comparison of the reconstruction position. Reviewed

    Kasuaya H, Nakao A, Nomoto S, Hosono J, Takeda S, Kaneko T, Takagi H.

    Hepatogastroenterology.   Vol. 44 ( 15 ) page: 856-860   1997.5

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

▼display all

Books 8

  1. 現代医学65巻2号・癌免疫療法トピックス

    粕谷 英樹,一ノ瀬 亨,直江 吉則,松村 繁,Itzel Bustos,炭竈 誠二,長谷川 仁紀,Branko Aleksic( Role: Joint author)

    愛知県医師会  2017.12 

     More details

    Language:Japanese

  2. Innovation of Diagnosis and Treatment for Pancreatic Cancer Part 4, Chap. 18 The Potential of Oncolytic Virus Therapy for Pancreatic Cancer

    Hideki Kasuya( Role: Joint author)

    Springer  2017.8 

     More details

    Language:English Book type:Scholarly book

  3. 遺伝子医学MOOK 31号 がん免疫療法 - What's now and what's next? 第2章の4の3) 腫瘍溶解性ウイルスHF10による再発乳がん多発結節症例, 切除不能進行膵がん症例に対する臨床研究

    粕谷 英樹, 直江 吉則, 一ノ瀬 亨, 廣岡 芳樹, 後藤 秀実, 田中 舞紀( Role: Joint author)

    (株)メディカル ドゥ  2017.7 

     More details

    Language:Japanese Book type:Scholarly book

  4. 次世代がん治療 ~発症・転移メカニズムからがん免疫療法・ウイルス療法、診断法まで~

    粕谷 英樹 他( Role: Joint author)

    (株)エヌ・ティー・エス  2017.6 

     More details

    Language:Japanese Book type:Scholarly book

  5. 次世代のがん治療薬・診断のための研究開発

    粕谷 英樹、他98名( Role: Joint author)

    (株)技術情報協会  2016.2 

     More details

    Total pages:400   Language:Japanese Book type:Scholarly book

  6. 分子細胞治療フロンティア2015、chapter 3. 腫瘍溶解性ウイルスHF10: Combination Therapyの有用性

    粕谷英樹、小寺泰弘、山田豪、後藤秀実、廣岡芳樹、川嶋啓揮、田中舞紀( Role: Joint author)

    飯田橋パピルス  2014.8 

     More details

    Language:Japanese Book type:Scholarly book

  7. 肝胆膵疾患の診断と治療トピックス2006 (Oncolytic virus therapyを使用した膵癌への挑戦)

    ( Role: Joint author)

    株式会社アークメディア  2006.10 

     More details

    Language:Japanese

  8. ミレニアム消化器2000 (進行膵癌に対する集学的治療としての遺伝子治療)

    粕谷英樹,木全秀人,中尾昭公( Role: Joint author)

    株式会社 日本メディカルセンター  2001.2 

     More details

    Language:Japanese

▼display all

Research Project for Joint Research, Competitive Funding, etc. 9

  1. 腫瘍溶解性ウイルスHF10を使用した、からだに優しい癌治療

    2008.7 - 2009.3

    学内共同研究 

  2. 長期間持続的効果の確認された腫瘍溶解性ウイルスを用いた癌臨床試験

    2008.6 - 2009.5

    学内共同研究 

  3. 安全でより強力な抗腫瘍効果を持つ新規ヘルペスウイルスベクターの開発

    2007.12 - 2008.12

    学内共同研究 

  4. 単純ヘルペスウイルスを用いた癌のウイルス療法

    2007.4 - 2008.3

    学内共同研究 

  5. Deveropment of inovative cancer therapy using mutannt herpes virus, and Phase I/II study

    2007.4

    Cooperative Research within an Affiliated University or Institute 

  6. Cancer therapy using mutant herpes virus (HF10)

    2005.4 - 2006.3

    Cooperative Research within an Affiliated University or Institute 

  7. Cancer therapy against abdominal tumor using mutant herpes virus

    2004.10 - 2005.3

    Cooperative Research within an Affiliated University or Institute 

  8. New strategy against disseminated pancreatic cancer using mutant herpes virus

    1999.4 - 2001.3

    Cooperative Research within an Affiliated University or Institute 

  9. 膵癌におけるAAVベクターを用いた遺伝子治療の基礎的研究

    1996.4 - 1998.3

    学内共同研究 

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 15

  1. 固形癌に対するCAR-T、ウイルス療法の併用による新規免疫療法の開発

    Grant number:21H02999  2021.4 - 2024.3

    科学研究費助成事業  基盤研究(B)

    粕谷 英樹, 直江 吉則, 松村 繁

      More details

    Authorship:Principal investigator 

    Grant amount:\17420000 ( Direct Cost: \13400000 、 Indirect Cost:\4020000 )

    本研究は、腫瘍溶解性ウイルスとCAR-T細胞との併用でより強力な癌免疫療法を確立することを目的とし、T細胞の集族を向上させるケモカインRANTESとT細胞誘導標識抗原とを同時に発現する次世代型腫瘍溶解性ウイルスを開発することによって、CAR-T細胞を意図的に腫瘍に集簇させ、これに派生する以下の問いに解答を得ることで医療に貢献すると共に、幅広く研究者に有益な学術的情報を提供する。

  2. 癌を支える癌関連間葉系幹細胞の癌ワクチンへの標的化

    Grant number:18H02691  2018.4 - 2022.3

    科学研究費助成事業  基盤研究(B)

    松村 繁, 粕谷 英樹, 直江 吉則, 一ノ瀬 亨

      More details

    Authorship:Coinvestigator(s) 

    改変ウイルス作製は、現在第一段階:ゲートウェイシステムを組み込んだウイルス作製を終了し、ゲートウェイrecombinationにてinsert部分をウイルスゲノムに直接組み替えれることを確認したところである。組み換え用に必要なコンストラクトの作成を並行して行っている。引き続きウイルス作製を遂行していく予定である。レトロウイルス感染により蛍光ラベルした間葉系幹細胞を腫瘍内投与後、腫瘍溶解性ウイルスによって治療を行った後、腫瘍組織を酵素的にばらばらにし、残存間葉系幹細胞を調べた。まだ、確認作業中ではあるが、特別に遺伝子改変していない親株腫瘍溶解性ウイルスでも60%以上の間葉系幹細胞を殺すことができているようであった。ウイルス改変は、当初のように間葉系幹細胞でのみ活性の高いプロモーターを使う必要がないと思われる結果である。引き続き、ジフテリア毒素とジフテリア毒素受容体(HBEGF)による選択的殺細胞の系確立を進めていく。これにより、間葉系幹細胞を選択的に殺す系の確立を目指すとともに、腫瘍溶解性ウイルスとの比較を行っていく予定である。
    KPC(LSL-Kras G12D/+; LSL-Trp53R172H/+; Pdx-Cre)マウスにできた膵癌より単離された膵癌細胞株KPC 細胞を九州大学より供与して頂いた。この膵癌細胞を用いて癌細胞の癌幹細胞を蛍光ラベルするための系を構築している。ALDH1プロモーターを用いたコンストラクトへ計画を変更しALDH1プロモーター:dGFPのコンストラクトは既にKPC細胞株を樹立した。予想通り、dGFP陽性細胞は割合も少なく、癌幹細胞を模しているのではないかと思われる。現在、他の膵臓癌幹細胞マーカーCD133やCD44を用いて検証中である。ALDH1プロモーター:CreERT2のコンストラクトももう少しで完成である。
    やっとマウスを用いた実験での検証にたどり着いた感がある。最終年度ではあるが、当初の目標を達成すべく実験を繰り返していく予定である。
    ここまで進めたものを、ひとつひとつ確かめながら着実に進めていく予定である。ウイルス改変に関しては、搭載するべき遺伝子に変更を加える必要があるように思われる。間葉系幹細胞を用いたウイルス感染実験は逆に治療法として有用なのではないかと考えを深めている。癌幹細胞がマウス腫瘍内でどのようにマーカーとして働いているのか、細胞系譜追跡の系を立ち上げることと並行して検証していく。

  3. TCR sequencing of tumor infiltrating T cells using iPS cell technology

    Grant number:17K19696  2017.6 - 2019.3

    Grant-in-Aid for Challenging Research (Exploratory)

    Naoe Yoshinori

      More details

    Authorship:Coinvestigator(s) 

    By collecting tumor-specific cytotoxic T cells infiltrating the mouse tumor and introducing Yamanaka factor, it was possible to obtain a cell population that proliferates without anti-CD3 antibody stimulation. These cells were judged as iPS cells because they proliferated without TCR stimulation. In addition, we confirmed a gene rearrangement of the TCRb in all the proliferating cells examined. From the above, it was suggested that cells proliferating without anti-CD3 stimulation are derived from T cells. In addition, we tried to establish iPS cells using human peripheral cytotoxic T cells, but the establishment efficiency was low. In the future, we will investigate culture conditions and try to improve the establishment efficiency.

  4. Role of immune cells in anti-tumor effect of HF10

    Grant number:16H05413  2016.4 - 2019.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

    Kasuya Hideki

      More details

    Authorship:Principal investigator 

    Grant amount:\17420000 ( Direct Cost: \13400000 、 Indirect Cost:\4020000 )

    HF10 showed a strong antitumor effect on squamous cell carcinoma cell line SCC7. Furthermore, a synergistic antitumor effect was observed in combination with the PD-L1 antibody. Next, we examined what kind of immune cells infiltrated into the tumor. As a result, infiltration of T cells, macrophages, NK cells and dendritic cells was observed at a high rate in the tumors administered in the HF10 and HF10 / anti-PD-L1 antibody combination group. On the other hand, in non-treated tumors, T cell infiltration was found at a high rate. From this, infiltration of immune cells into the tumor was observed in the HF10 and HF10/anti-PD-L1 antibody combination group, which suggested that infiltration of these immune cells was involved in the enhancement of the combined effect.

  5. HF10ウイルスの抗腫瘍効果における新たな免疫因子の役割

    2016.4 - 2019.3

    科学研究費補助金  基盤研究(B)

    粕谷英樹

      More details

    Authorship:Principal investigator 

  6. Development of innovative combination therapy of tumor antigen virus and TCR gene-modified T cells

    Grant number:16K15611  2016.4 - 2018.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Challenging Exploratory Research

    KASUYA Hideki

      More details

    Authorship:Principal investigator 

    Grant amount:\3380000 ( Direct Cost: \2600000 、 Indirect Cost:\780000 )

    In this study, we investigated the possibility of novel therapeutic approach for cancer based on the combination of transgenic HF10, the oncolytic herpes simplex virus that genetically modified to express cancer-specific antigen, and TCR gene-modified T cells recognizing cancer antigen produced from transgenic HF10. We steadily advanced the preparation of research by establishing the cancer antigen-expressing cells and confirming the cell-killing effect of T cells. We examined the usefulness of novel genomic editing technology for homologous recombination efficiency, and found that novel genomic editing is a very suitable technique for improvement of homologous recombination and purification of genetically modified virus. In the future, we will advance the development of cancer antigen gene-carrying HF10 using this technology, accumulate basic data on combination therapy with antigen specific TCR gene-modified T cells, and explore the possibility of clinical application.

  7. 革新的な腫瘍抗原ウイルスとTCR遺伝子改変T細胞の併用療法の開発

    2016.4 - 2018.3

    科学研究費補助金  挑戦的萌芽研究

    粕谷英樹

      More details

    Authorship:Principal investigator 

  8. 腫瘍溶解性ウィルスHF10吸着化リンパ球による新規治療法の開発

    2013.4 - 2016.3

    科学研究費補助金  基盤研究(B),課題番号:25293275

    粕谷 英樹

      More details

    Authorship:Principal investigator 

  9. 腫瘍溶解性ウィルスによる新規消化管癌治療法の開発

    2011.4 - 2014.3

    科学研究費補助金  基盤研究(C),課題番号:23590922

    森 義徳

      More details

    Authorship:Coinvestigator(s) 

  10. トリプルアレイ法を応用した新規がん関連遺伝子の同定

    2010.4 - 2013.3

    科学研究費補助金  基盤研究(C),課題番号:22591427

    野本 周嗣

      More details

    Authorship:Coinvestigator(s) 

  11. EGCGによるAP-1を介した肝細胞癌発生抑制に関する研究

    2010.4 - 2013.3

    科学研究費補助金  基盤研究(C)

    藤井努

      More details

    Authorship:Coinvestigator(s) 

    EGF 遺伝子導入マウスの肝癌組織を採取したところ、c-jun の発現が増加し, AP-1 の活性が上昇していることが示された。また、同マウスに EGCG を経腹膜投与することにより、肝細胞癌発生が抑制された。これは、我々が以前に示した in vitro の結果を、in vivo で実証する結果となった。さらに、切除したヒト肝癌組織のシグナル伝達経路を検討したところ、c-jun 活性が高発現しているものは低発現群より無再発生存率が有意に低いことが示された。

  12. リンパ球ヒッチハイク法による抗腫瘍ウイルス療法

    2009.4 - 2012.3

    科学研究費補助金  基盤研究(C),課題番号:21591662

    粕谷 英樹

      More details

    Authorship:Principal investigator 

  13. Inta venous injection of Oncolytic virus against liver metastasis

    2008.4 - 2011.3

    Grant-in-Aid for Scientific Research 

      More details

    Authorship:Coinvestigator(s) 

  14. Influence of mutation type of p53-FGF-1 pathway in angiogenesis for cancerous tissue and metastasis

    2007.4 - 2009.3

    Grant-in-Aid for Scientific Research 

      More details

    Authorship:Coinvestigator(s) 

  15. Oncolytic Viral Therapy Using Mutant Herpes Simplex Virus (HF10) for Cancer

    2004.4 - 2007.3

    Grant-in-Aid for Scientific Research 

      More details

    Authorship:Coinvestigator(s) 

▼display all

Industrial property rights 1

  1. キメラ標的因子受容体(PCT出願)

    粕谷英樹

     More details

    Application no:PCT/JP2021/043978  Date applied:2021.11

    Patent/Registration no:PCT/JP2021/043978